Royalty Pharma plc
RPRX
Rank in Stocks
#885
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Share Price
$61.10
Last synced: 2026-10-16
Market Cap
$27.21B
Change (1 day)
2.48%
Change (1 year)
65.09%
Country
US
Trade Royalty Pharma plc (RPRX)
Category
Healthcare
EPS for Royalty Pharma plc (RPRX)
EPS as of June 2026 TTM: $2.41
According to Royalty Pharma plc latest financial reports and stock price the company's current EPS (TTM) is $2.41. At the end of 2024 the company had a EPS of $1.92 a decrease compared to its 2023 EPS that were of $2.54.
EPS history for Royalty Pharma plc from 2015 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $2.41 | 34.64% |
| 2025 | $1.79 | -6.61% |
| 2024 | $1.92 | -24.41% |
| 2023 | $2.54 | 2,492.43% |
| 2022 | $0.10 | -93.45% |
| 2021 | $1.49 | -42.47% |
| 2020 | $2.60 | -59.54% |
| 2019 | $6.42 | 182.80% |
| 2018 | $2.27 | 13.86% |
| 2017 | $1.99 | 113.83% |
| 2016 | $0.93 | -2.67% |
| 2015 | $0.96 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -99.22% |
HK
|
|
| $0.52 | -78.42% |
US
|
